IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH α CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM Vα-Jα, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS
The present invention is an immunotherapeutic agent containing NKT cells obtained by differentiating cells in which the α chain of a TCR gene has been rearranged to a uniform Vα-Jα in a form specific to NKT-cell receptors in vitro, and provides an agent targeting the administration of allogeneic individuals in which the NKT cells and at least a single locus genotype among MHC gene loci are incongruous. Furthermore, the present invention provides a bank of NKT cells derived from human cells or said cells in which the α chain of a TCR gene has been rearranged to a uniform Vα-Jα. This agent and cell bank are useful for preventing and/or treating cancer, infectious diseases, allergic diseases and autoimmune disorders.
